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Abstract
Cytochrome P450-derived epoxyeicosatrienoic acids are potent vasodilators in preclinical models
and are hydrolyzed by soluble epoxide hydrolase (EPHX2). Associations between the EPHX2
Lys55Arg and Arg287Gln polymorphisms and cardiovascular disease risk have been reported;
however, their impact on vascular function in humans has not been investigated. In 265 volunteers
(198 white, 67 black American), forearm blood flow was measured by strain-gauge venous
occlusion plethysmography at baseline and in response to bradykinin, methacholine and sodium
nitroprusside. Forearm vascular resistance was calculated as mean arterial pressure/forearm blood
flow. In white Americans, Lys55Arg genotype was associated with vasodilator response to
bradykinin, such that forearm blood flow was significantly lower (P=0.043) and forearm vascular
resistance was significantly higher (P=0.013) in Arg55 variant allele carriers compared to wild-
type individuals. Significant associations were also observed with methacholine and sodium
nitroprusside. In contrast, no relationship was observed in black Americans. In black Americans,
Arg287Gln genotype was associated with vasodilator response to bradykinin. Although the
difference in forearm blood flow did not reach statistical significance (P=0.058), forearm vascular
resistance was significantly lower (P=0.037) in Gln287 variant allele carriers compared to wild-
type individuals. Significant associations were also observed with methacholine and sodium
nitroprusside. In white Americans, Gln287 variant allele carriers did not exhibit significantly
higher forearm blood flow (P=0.128) or lower forearm vascular resistance (P=0.080). Genetic
variation in EPHX2 is associated with forearm vasodilator responses in a bradykinin receptor- and
endothelium-independent manner, suggesting an important role for soluble epoxide hydrolase in
the regulation of vascular function in humans.
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INTRODUCTION
Cytochrome P450 (CYP) epoxygenase enzymes from the CYP2J and CYP2C subfamilies
catalyze the oxidative metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs).1
EETs are synthesized in the endothelium and cause vasodilation in numerous vascular beds
via activation of calcium-sensitive potassium channels (BKCa) and smooth muscle cell
hyperpolarization.2,3 Consequently, CYP-derived EETs are regarded as one of the primary
endothelium-derived hyperpolarizing factors (EDHFs).2 Soluble epoxide hydrolase (sEH)
rapidly hydrolyzes EETs to less biologically active dihydroxyeicosatrienoic acid (DHET)
metabolites.4 Pharmacological inhibition of sEH increases cellular and circulating EET
levels, potentiates EET-mediated vasodilation, and lowers blood pressure in preclinical
models.4–6 Importantly, sEH inhibitors are currently in clinical development for the
treatment of hypertension.
Associations between polymorphisms in the gene encoding sEH (EPHX2) and
cardiovascular and cerebrovascular disease risk in humans have been recently reported.7–13
Most notably, the nonsynonymous Arg287Gln and Lys55Arg polymorphisms exhibit lower
and higher sEH metabolic activity in vitro, respectively.14–16 The Gln287 variant allele has
been associated with a lower prevalence of ischemic stroke in a Chinese population,8
although the presence and strength of this relationship has been inconsistent across studies
and racial groups.9,10,17 The Arg55 variant allele has been associated with significantly
higher risk of developing coronary artery disease and ischemic stroke events in populations
of European ancestry.11,12 Although multiple reports demonstrate presence of a significant
relationship between genetic variation in EPHX2 and cardiovascular and cerebrovascular
disease risk in humans,8–13 the role of sEH in the regulation of vascular function in humans
remains poorly understood. Due to their effects on sEH metabolic function in vitro, we
hypothesized that the Arg55 and Gln287 variant alleles, respectively, predispose individuals
to higher and lower vascular resistance in vivo. Consequently, we characterized the
relationship between genetic variation in EPHX2 and forearm vasodilator responses.
METHODS
Please see http://hyper.ahajournals.org for an expanded description of the methods.
Subjects
DNA was extracted from 265 healthy adults who participated in studies that evaluated
forearm vasodilator responses.18,19 All subjects gave written informed consent. The protocol
was approved by the Vanderbilt University Institutional Review Board and conducted
according to the Declaration of Helsinki.
Experimental Protocol
Forearm blood flow (FBF) was measured using strain-gauge venous occlusion
plethysmography (D.E. Hokanson, Bellevue, WA) at baseline and in response to incremental
doses of bradykinin (100, 200, and 400 ng/min; Clinalfa AG, Läufelfingen, Switzerland),
methacholine (3.2, 6.4, and 12.8 μg/min; Pharmaceutical Compounding Center, Nashville,
TN) and sodium nitroprusside (1.6, 3.2, and 6.4 μg/min; Gensia Siccor Pharmaceuticals,
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Irvine, CA), as described previously.18–21 Forearm vascular resistance (FVR) was
calculated as the ratio of mean arterial pressure/FBF.
Polymorphism Selection and Genotyping
In addition to the nonsynonymous Lys55Arg and Arg287Gln polymorphisms, eight
polymorphisms in EPHX2 with >5% frequency and r2 <0.80 were also genotyped for
haplotype construction (Table S1).
Statistical analysis
Due to previously reported racial differences in forearm vasodilator responses,18,21 all
analyses were stratified by race. Differences in FBF and FVR were determined using
general linear model repeated-measures ANOVA in which the within-subject variable was
vasoactive agent dose and the between-subject variables were genotype/haplotype group,
cigarette smoking status (yes/no), and body mass index (quartile).18,19 A post-hoc Scheffe’s
test was performed to identify between-group differences. Data are presented as least-
squares mean ± standard error (SE) unless otherwise indicated. To minimize the impact of
the multiple statistical tests conducted, we estimated the false discovery rate (FDR) q-value
for each comparison.11,22 Only q-values for statistically significant findings (P<0.05) are
presented.
RESULTS
EPHX2 Genotype and Subject Characteristics
Study subject characteristics and genotype distributions for the EPHX2 Lys55Arg and
Arg287Gln polymorphisms are presented in Table 1 according to race. No significant
differences in age, gender, cigarette smoking status, body mass index, or resting blood
pressure were observed across either genotype in either racial group (Table S2).
EPHX2 Genotype and Forearm Vasodilator Responses to Bradykinin
Bradykinin infusion increased FBF and decreased FVR in a dose-dependent fashion (Figures
1, 2 and 3), but did not significantly affect mean arterial pressure or heart rate (P=NS). Race,
cigarette smoking status and body mass index (ANOVA P<0.05), but not gender, were each
significant predictors of bradykinin-stimulated changes in FBF and FVR.
There was no relationship between Lys55Arg genotype and either resting FBF (P=0.932 and
P=0.876) or FVR (P=0.663 and P=0.752) in white and black American subjects, respectively
(Table S2). In white Americans, vasodilator response to bradykinin was significantly
associated with Lys55Arg genotype, such that FBF was significantly lower (Figure 1A,
P=0.043, q=0.078) and FVR was significantly higher (Figure 1C, P=0.013, q=0.047) in
Arg55 variant allele carriers (Lys/Arg or Arg/Arg) relative to wild-type (Lys/Lys)
individuals. In contrast, genotype differences were not observed in black Americans (Figure
1B and 1D).
Resting FVR was significantly lower in black American Gln287 variant allele carriers (Arg/
Gln or Gln/Gln) compared to wild-type (Arg/Arg) individuals (P=0.040, Table S2).
Although resting FBF also appeared to be higher in white and black Americans (P=0.086
and P=0.078, respectively), and FVR appeared to be lower in white Americans (P=0.053),
these differences were not statistically significant (Table S2). Vasodilator response to
bradykinin was associated with Arg287Gln genotype in black Americans. Although the
difference in FBF did not reach statistical significance (Figure 2B, P=0.058), FVR was
significantly lower (Figure 2D, P=0.037, q=0.072) in Gln287 variant allele carriers relative
to wild-type individuals. In white Americans, the observed differences in FBF (Figure 2A,
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P=0.128) and FVR (Figure 2C, P=0.080) were less substantial than those observed in black
Americans and were not statistically significant.
Inclusion of both Lys55Arg and Arg287Gln genotype in the model did not alter the
observed relationships between each individual polymorphism and FVR in either white
(Lys55Arg: P=0.017; Arg287Gln: P=0.171) or black Americans (Lys55Arg: P=0.731;
Arg287Gln: P=0.037). An exploratory analysis evaluating the combination of both
genotypes yielded consistent results (Figure S1).
EPHX2 Genotype and Forearm Vasodilator Responses to Methacholine and Sodium
Nitroprusside
Vasodilator responses to methacholine (P=0.021, q=0.063) and sodium nitroprusside
(P=0.006, q=0.039) were also significantly associated with Lys55Arg genotype in white
Americans (Table 2). As observed with bradykinin, FVR was significantly higher in
response to each agent in Arg55 variant allele carriers (Lys/Arg or Arg/Arg) relative to wild-
type (Lys/Lys) individuals. Significant genotype differences were not observed in black
Americans.
Arg287Gln genotype was associated with vasodilator responses to methacholine (P=0.033,
q=0.072; and P=0.025, q=0.063) and sodium nitroprusside (P=0.125; and P=0.006, q=0.039)
in both white and black Americans, respectively (Table 2). As observed with bradykinin,
FVR was lower at baseline and in response to each agent in Gln287 variant allele carriers
(Arg/Gln or Gln/Gln) relative to wild-type (Arg/Arg) individuals.
EPHX2 Haplotypes and Forearm Vasodilator Responses
Nine EPHX2 polymorphisms were included in haplotype construction, which identified six
common haplotypes (>5%) in white American subjects (Figure S2). Only one common
haplotype was tagged by the Lys55Arg polymorphism variant G allele, which had a
frequency of 13.7%. No differences in either resting FBF (P=0.471) or FVR (P=0.301) were
observed in subjects carrying the variant Arg55-tagged haplotype. Vasodilator response to
bradykinin, however, was significantly associated with this haplotype, such that FBF was
significantly lower (Figure 3A, P=0.016, q=0.053) and FVR was significantly higher (Figure
3B, P=0.004, q=0.039) in subjects carrying the Arg55-tagged haplotype. Similar results
were observed with Arg55-tagged haplotypes constructed using the sliding-window
approach (Figure S3). In response to incremental doses of methacholine and sodium
nitroprusside, respectively, FBF was significantly lower (P=0.025, q=0.063; and P=0.001,
q=0.016) and FVR was significantly higher (P=0.009, q=0.047; and P=0.001, q=0.016) in
subjects carrying the Arg55-tagged haplotype.
A distinct haplotype tagged by the Arg287Gln polymorphism variant A allele had a
frequency of 11.1%. Although carriers of the Gln287-tagged haplotype appeared to exhibit
higher resting FBF (P=0.127) and lower FVR (P=0.083), these differences were not
statistically significant. Similar results were observed with Gln287-tagged haplotypes
constructed using the sliding-window approach (Figure S3). No statistically significant
associations between the Gln287-tagged haplotype and vasodilator responses to incremental
doses of bradykinin (Figure 3C and 3D), methacholine (FBF: P=0.184, FVR: P=0.107) or
sodium nitroprusside (FBF: P=0.254, FVR: P=0.233) were observed.
DISCUSSION
Cytochrome P450 (CYP) epoxygenases catalyze endothelial EET biosynthesis. These potent
vasodilators are rapidly hydrolyzed by sEH, and pharmacological inhibition of sEH
potentiates the effect of EETs.1,2,4 This study identified a significant association between
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functional genetic variants in EPHX2, the gene which encodes sEH, and vascular function in
humans. Specifically, the Arg55 variant allele was associated with significantly lower FBF
and higher FVR in response to vasodilators in white Americans, while the Gln287 variant
allele was associated with higher FBF and lower FVR at baseline and in response to
vasodilators in black Americans. Similar genotype-phenotype relationships were observed in
response to bradykinin, methacholine and sodium nitroprusside, suggesting that the
mechanism underlying the functional link between sEH and forearm vascular
responsiveness in humans is both bradykinin receptor-and endothelium-independent.
Collectively, these data demonstrate a potentially important role for sEH in the regulation of
vascular function in humans, and offer important mechanistic insight into previously
reported associations between the EPHX2 Lys55Arg and Arg287Gln polymorphisms and
cardiovascular and cerebrovascular disease risk.
The nonsynonymous Lys55Arg polymorphism exhibits higher sEH metabolic activity in
vitro14,15 and in vivo,11 and has been associated with higher risk of coronary artery disease
and ischemic stroke events in individuals of European ancestry.11,12 Consistent with higher
sEH metabolic activity and EET hydrolysis, white American carriers of the Arg55 variant
allele exhibited lower vasodilation responses compared to wild-type individuals. Lower
vasodilation responses were also observed in carriers of the Arg55-tagged haplotype,
suggesting that Lys55Arg is the functional allele driving these associations. We cannot rule
out, however, that Lys55Arg is simply a marker in linkage disequilibrium with the true
causative locus. In contrast, there was no association between Lys55Arg genotype and either
resting or agonist-stimulated changes in FBF or FVR in black American subjects. Although
the mechanism underlying the racial differences in this genotype-phenotype relationship is
not known, these findings are consistent with the prior observation that Lys55Arg genotype
was associated with sEH metabolic activity in vivo and cardiovascular disease risk in white,
but not black, Americans enrolled in the Atherosclerosis Risk in Communities (ARIC)
study.11
Multiple studies have demonstrated that the Arg287Gln polymorphism exhibits significantly
lower sEH metabolic activity and EET hydrolysis in vitro,14–16 although its functional
impact on sEH metabolic activity in vivo remains unknown. Epidemiological studies provide
inconsistent data regarding the presence and direction of a significant relationship between
the Arg287Gln polymorphism and risk of cardiovascular and cerebrovascular events.8–13,17
Consistent with the vascular protective effects associated with sEH inhibition in preclinical
models,4 the Gln287 variant allele was recently associated with a significantly lower risk of
ischemic stroke in a Chinese population.8 In contrast, the Gln287 variant allele was
associated with a higher prevalence and extent of coronary artery calcification in black
Americans9 and insulin resistance in Japanese type 2 diabetics.23 Similarly, in contrast to the
neuronal protective effects conferred by the Gln287 variant allele in vitro,15 an association
with significantly higher risk of ischemic stroke was reported in a white European
population.10 No association with coronary artery disease and ischemic stroke risk has been
observed in other white or black American11,13 and European populations.12,17 Collectively,
these conflicting data demonstrate that the functional relevance of the Arg287Gln
polymorphism in humans remains unclear and requires further study.
Consistent with the hypothesis that decreased endogenous sEH metabolic activity enhances
the vasodilator effects of EETs, Gln287 variant allele carriers demonstrated higher FBF and
lower FVR under basal and agonist-stimulated conditions compared to wild-type individuals
in the current investigation. These data are also consistent with the observation that
administration of pharmacological inhibitors of sEH cause vasodilation in preclinical models
and isolated human vessels.4–6 The observed relationship between the Arg287Gln
polymorphism and vasodilator responses was more pronounced in black American subjects
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compared to the white American subjects studied. Although the current study was
underpowered to investigate genotype-by-genotype interactions in each racial group, an
interaction between the Lys55Arg and Arg287Gln polymorphisms appears unlikely to
account for the observed racial differences.
The Lys55Arg and Arg287Gln polymorphisms were associated with altered vasodilation
responses to both bradykinin and methacholine. These endothelium-dependent vasodilators
cause vascular relaxation in part by stimulating the endothelial formation of EETs, which
subsequently hyperpolarize vascular smooth muscle.2 Somewhat unexpectedly, these
functional variants in EPHX2 also affected the endothelium-independent vasodilator
response to sodium nitroprusside. Although it is well-established that endothelial-derived
EETs act as paracrine mediators of vasodilation,2 EPHX2 deletion and pharmacological sEH
inhibition also attenuate vascular remodeling in preclinical models by potentiating the anti-
proliferative and anti-inflammatory effects of EETs.24,25 Our findings suggest that chronic
inter-individual differences in EET exposure based on Lys55Arg and Arg287Gln genotype
could contribute to physiological differences in forearm vascular responsiveness via an
effect on vascular remodeling. An important limitation of our work, however, is the lack of
functional data demonstrating that Arg55 and Gln287 variant allele carriers, respectively,
exhibit higher and lower EET hydrolysis in vivo. Further studies will be necessary to
characterize the direct effects of exogenous EET administration and sEH inhibition on
vasodilation and vascular remodeling in humans, and define the underlying mechanisms.
Moreover, although in vitro studies have demonstrated that the Arg55 and Gln287 variant
alleles elicit lower and higher sEH phosphatase activity, respectively,26,27 the potential
contribution of sEH phosphatase activity to the association between EPHX2 polymorphisms,
vascular function, and cardiovascular and cerebrovascular risk remains unknown and
requires further investigation.
This study examined the vascular effects of EPHX2 polymorphisms in one of the largest
cohorts that directly measured vasodilation responses to infused agonists. Nevertheless, the
relatively small sample size represents a limitation since we may have been underpowered to
detect an association, particularly in the black Americans studied. Moreover, due to the very
low number of homozygous Arg55 and Gln287 carriers, we were only powered to
characterize these relationships using a dominant genetic model of inheritance. In the
bradykinin studies, there was excellent power to detect a 30% difference in FVR across the
Lys55Arg (β=0.97) and Arg287Gln (β=0.94) genotype groups in the white American subset.
The power to detect these differences in the black American subset was considerably less
(Lys55Arg: β=0.67; Arg287Gln: β=0.52). We also made multiple comparisons and there is a
possibility of false positive associations. In order to account for this possibility, we
calculated a FDR q-value for each comparison. Although no gold-standard q-value threshold
has been established to identify “true” associations, incorporation of this statistical approach
into candidate gene association studies has become an increasingly recognized method to
account for multiple comparisons and enhance confidence in observed associations.28 Since
all q-values were estimated to be <0.08, we have a higher level of confidence in our reported
findings. Importantly, validation in a well-powered, independent population will be
ultimately necessary to confirm presence of a functional relationship between genetic
variation in EPHX2 and vasodilator responses in humans.
PERSPECTIVES
Cytochrome P450 epoxygenases catalyze the biosynthesis of EETs, which are potent
vasodilators that undergo rapid hydrolysis by sEH. Although associations between
polymorphisms in EPHX2 and cardiovascular and cerebrovascular disease risk have been
recently reported, their impact on vascular function has remained unknown. The current
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study demonstrates that genetic variation in EPHX2 is significantly associated with
vasodilator responses in humans. Specifically, carriers of the increased function Arg55 and
decreased function Gln287 variant alleles were predisposed to attenuated and enhanced
forearm vasodilator responses, respectively. Collectively, these findings suggest that sEH
has an important role in the regulation of vascular resistance and blood pressure in humans,
and offer important mechanistic insight into previously reported associations between the
EPHX2 Lys55Arg and Arg287Gln polymorphisms and cardiovascular and cerebrovascular
disease risk. Pharmacological inhibition of sEH is currently under clinical development as a
novel therapeutic strategy for the treatment of hypertension. These findings may ultimately
help identify specific subsets of the population who may be more (Arg55 carriers) or less
(Gln287 carriers) likely to respond to the anti-hypertensive effects of sEH inhibitors.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. EPHX2 Lys55Arg polymorphism and vasodilator responses to bradykinin
Least-squares mean ± SE FBF (A, B) and FVR (C, D) at baseline and in response to
incremental doses of bradykinin (BK, 100 and 200 ng/min) among EPHX2 Lys55Arg
genotype groups in white (A, C) and black (B, D) Americans. The repeated-measures
ANOVA P-value for the genotype group comparison is provided. *Post-hoc P<0.05 versus
wild-type (Lys/Lys).
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Figure 2. EPHX2 Arg287Gln polymorphism and vasodilator responses to bradykinin
Least-squares mean ± SE FBF (A, B) and FVR (C, D) at baseline and in response to
incremental doses of bradykinin (BK, 100 and 200 ng/min) among EPHX2 Arg287Gln
genotype groups in white (A, C) and black (B, D) Americans. The repeated-measures
ANOVA P-value for the genotype group comparison is provided. *Post-hoc P<0.05 versus
wild-type (Arg/Arg).
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Figure 3. EPHX2 haplotypes and vasodilator responses to bradykinin in white Americans
Least-squares mean ± SE FBF (A, C) and FVR (B, D) at baseline and in response to
incremental doses of bradykinin (BK, 100, 200 and 400 ng/min) among those carrying the
Arg55-tagged (C, D) and Gln287-tagged (E, F) haplotypes compared to all other EPHX2
haplotypes (Hap-WT). The repeated-measures ANOVA P-value for the haplotype group
comparison is provided. *Post-hoc P<0.05 versus all other haplotype groups (Hap-WT).
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Table 1
Subject characteristics and EPHX2 genotype by race.
Characteristic* White American Black American
N 198 67
Age (years) 31.6 ± 10.5 32.7 ± 10.8
Gender (% female) 88 (44.4%) 41 (61.2%) †
Smoker (% yes) 19 (9.6%) 4 (6.0%) †
BMI (kg/m2) 24.5 ± 3.4 26.0 ± 4.0 †
MAP (mmHg) 83.4 ± 8.3 86.9 ± 11.2 †
FBF (mL/100mL tissue/min) 4.2 ± 2.0 3.9 ± 1.7
FVR (mmHg/mL/100mL tissue/min) 24.2 ± 10.6 27.5 ± 13.5 †
Lys55Arg
 A/A (Lys/Lys) 135 (70.0%) 42 (62.7%)
 A/G (Lys/Arg) 56 (29.0%) 24 (35.8%)
 G/G (Arg/Arg) 2 (1.0%) 1 (1.5%)
Arg287Gln
 G/G (Arg/Arg) 152 (78.4%) 53 (81.5%)
 G/A (Arg/Gln) 39 (20.1%) 10 (15.4%)
 A/A (Gln/Gln) 3 (1.6%) 2 (3.1%)
*
Data presented as mean ± standard deviation or count (proportion).
†
P<0.05 versus white American. There were no statistically significant differences in genotype distribution or allelic frequency between racial
groups for either polymorphism (P>0.30 for each comparison).
BMI=body mass index, MAP=mean arterial pressure, FBF=baseline forearm blood flow, FVR=baseline forearm vascular resistance.
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